The safety and efficacy of BCG combined with mitomycin C compared with BCG monotherapy in patients with non-muscle-invasive bladder cancer: A systematic review and meta-analysis

• Published in: Open medicine (Warsaw, Poland) Vol. 20; no. 1; pp. 20241134 - 49
• Main Authors: Liu, Jianping, Zhou, Weijian, Zhang, Wei, Chang, Congwang, Zhang, Peng, Fu, Guanghua
• Format: Journal Article
• Language: English
• Published: Poland De Gruyter 26.03.2025; Walter de Gruyter GmbH
• Subjects: Bacillus Calmette-Guérin; Bladder cancer; intravesical therapies; mitomycin C; Mortality; non-muscle-invasive bladder cancer; Review; urinary bladder neoplasms; intravesical therapies; Bacillus Calmette-Guérin; urinary bladder neoplasms; mitomycin C; non-muscle-invasive bladder cancer
• ISSN: 2391-5463; 2391-5463
• DOI: 10.1515/med-2024-1134

We sought to determine the efficacy and safety of Bacillus Calmette-Guérin (BCG) combined with mitomycin C (MMC) compared with BCG monotherapy in intravesical therapies for non-muscle-invasive bladder cancer (NMIBC). We followed the recommended PRISMA guidelines for systematic reviews. Systematic literatures were performed on PubMed, EMBASE, Cochrane Library, CNKI, CBM, VIP, Wan Fang, and Clinical Trials.gov. Randomized controlled trials (RCTs) comparing BCG combined with MMC and BCG monotherapy in intravesical therapies for non-muscle-invasive bladder cancer patients were searched until August 1, 2023. This meta-analysis included 11 RCTs with a total of 1,349 subjects. Compared with BCG monotherapy, BCG combined with MMC was associated with lower disease recurrence rate (relative risk [RR] 0.66, 95% confidence interval [CI]: 0.56-0.77, < 0.00001), disease progression rate (RR 0.61, 95% CI: 0.44-0.84, = 0.003), and disease-specific mortality (RR 0.46, 95% CI: 0.26-0.78, = 0.004). However, there was a higher incidence of systemic adverse reactions (RR 1.57, 95% CI: 1.22-2.02, = 0.0004). There was no significant difference in the incidence of local adverse reactions (RR 1.07, 95% CI: 0.95-1.20, = 0.26) and all-cause mortality (RR 0.80, 95% CI: 0.62-1.03, = 0.08) between the two groups. BCG combined with MMC was associated with a decreased risk of bladder cancer recurrence and disease progression compared with BCG monotherapy. However, there was no significant difference in the incidence of local adverse events and all-cause mortality between the two groups. Due to the limitations of the number and quality of the included studies, more high-quality RCTs are needed to further explore the efficacy and safety of combined therapies.